Nastech Regains Teriparatide From P&G

Nastech Pharmaceutical has reacquired the rights to PTH1-34 nasal spray, a treatment for osteoporosis, from its collaboration partner Procter & Gamble (P&G) Pharmaceuticals.

The reacquisition follows notification of P&G’s decision to terminate the development and commercialization agreement for PTH1-34 (teriparatide) nasal spray.

Nastech will immediately advance the spray into a Phase II study to evaluate the change in bone mineral density, which the FDA has previously indicated will be the primary endpoint for approval, Nastech said.